Future savings from specialty pharmacies will come at pharma companies' expense.
Thomas Baker
Advertisement
Articles by Thomas Baker
Advertisement
Latest Updated Articles
Specialty Therapies Lose Special StatusPublished: September 1st 2004 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Leading in the Psychedelic Space: Q&A with Tarek Rabah
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program
5